bluuebunny/crossref_metadata_2025_split huggingface dataset:
Splenic flexure adenocarcinoma: A national cohort analysis of extent of surgical resection and outcomes
Authors: Kohn Julia F. , Boatman Sonja , Wang Qi , Marmor Schelomo , Hassan Imran , Madoff Robert D. , Gaertner Wolfgang B. , Goffredo Paolo 
Published: September 2024

AbstractAimThe optimal extent of resection for splenic flexure adenocarcinoma remains debated. These tumours straddle the left‐ and right‐sided vasculature with lymphatic drainage in a watershed area; current guidelines recommend either segmental or extended colectomy. We analysed surgical management of splenic flexure tumours and compared outcomes between approaches.MethodThe Surveillance, Epidemiology and End Results database was searched for adults with Stage I–III splenic flexure adenocarcinoma, 2004–2019.ResultsOf 5238 patients, 55% underwent extended colectomy. Compared to segmental colectomy, these patients were more likely to have advanced stage. On multivariable analysis, age ≤ 65 years remained independently associated with extended colectomy. Although fewer nodes were examined in segmental colectomy (median 14 vs. 16, p < 0.001), the number of positive nodes (both, median 0 [interquartile ratio 0–2], p = 0.20) and the lymph node ratio were similar between cohorts. Surgical approach was not significantly associated with increased positive nodal yield in adjusted analyses. Five‐year overall and disease‐specific survival were 73% and 84% for segmental and 72% and 83% for extended colectomy (p > 0.4); these remained comparable after adjustment.ConclusionsNationally, we observed similar rates of segmental and extended colectomy for splenic flexure adenocarcinoma. Extended colectomy was not more common in Stage III disease, indicating lack of stage migration, and was not associated with better oncological outcomes. These observations support current practice involving either approach, which should be tailored to patient‐related factors and preferences, while considering technical aspects and quality of life.
Temporal and trophic niche partitioning among arboreal ants in a Neotropical woodland savanna
Authors: Zuanon Lino Abdelnour , Quero Adilson , Neves Karen Christina , Vasconcelos Heraldo Luis 
Published: September 2024

Abstract
Niche partitioning is a key mechanism for explaining species coexistence, including the coexistence of ants in trees of the Brazilian savanna (cerrado). However, we have limited information on the extent to which arboreal ant species exploit different food resources and/or have different daily foraging schedules.
We tested these ideas through a baiting experiment, and by measuring the isotopic signature (δ15N) and the critical thermal maximum (CTmax) of the 14 most common species found in a typical cerrado tree species. Although most species foraged on all bait types offered, species‐specific preferences were noted for about one‐third of the species. We also found a wide variation in mean δ15N between species, reflecting interspecific differences in trophic position.
Most (71.4%) species foraged predominantly on a given period of the day, ranging from strictly nocturnal species to those that foraged mainly in the afternoon. Species with a higher heat tolerance (higher CTmax) often foraged at warmer periods of the day than those with a lower tolerance.
Despite the evidence of trophic and temporal niche partitioning, other mechanisms, such as nesting site specialization and behavioural trade‐offs, are required to explain species coexistence in this arboreal ant assemblage, as several species pairs largely overlapped both in their diet and time of foraging. Importantly, our results provide additional support for the idea that physiological restriction to high temperatures is important for understanding interspecific differences in foraging activity schedules.
Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study
Authors: Jensen Anne Birthe Helweg , Andersen Helene Riis Pontoppidan , Jensen Sarah Thorius , Jensen Christina Friis , Amstrup Jesper , Mathiasen René , Henriksen Kasper Amund , Hasle Henrik , Callesen Michael Thude , Brix Ninna 
Published: September 2024

ABSTRACTObjectivesChildhood cancer often presents with non‐specific signs and symptoms that might mimic non‐malignant disorders including musculoskeletal diseases, potentially leading to rheumatic and orthopaedic misdiagnoses. We aimed to compare clinical presentation, diagnostic interval and survival in paediatric acute myeloid leukaemia (AML) with and without initial musculoskeletal symptoms.MethodsThis nationwide retrospective, cohort study reviewed medical records of 144 children below 15 years diagnosed with AML in Denmark from 1996 to 2018.ResultsMusculoskeletal symptoms occurred in 29% (42/144) of children with AML and 8% (11/144) received an initial musculoskeletal misdiagnosis, being mainly non‐specific and pain‐related. The children with and without musculoskeletal symptoms did not differ markedly up to the diagnosis of AML and blood counts were affected equally in both groups. However, the children with prior musculoskeletal symptoms were more likely to have elevated levels of LDH and ferritin. Furthermore, they revealed a tendency towards a longer total interval (median 53 days vs. 32 days, p = 0.07), but the overall survival did not differ.ConclusionAML should be considered as an underlying cause in children with unexplained musculoskeletal symptoms and abnormal blood counts. Concomitant elevation of LDH and ferritin should strengthen the suspicion.
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma
Authors: Mazzoni Camilla , Argnani Lisa , Casadei Beatrice , Broccoli Alessandro , Gabrielli Giulia , Fabbri Nicole , Gugliotta Gabriele , Pellegrini Cinzia , Carella Matteo , Bagnato Gianmarco , Gentilini Marianna , Morigi Alice , Maglio Pierluca , Cantelli Martina , Stefoni Vittorio , Zinzani Pier Luigi 
Published: September 2024

ABSTRACTFirst‐line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional treatment and systemic chemo‐immunotherapy, can be used depending on the site and stage of disease. Single‐agent rituximab is a useful approach in the setting of localized, low‐intermediate risk EMZL. The aim our research was to analyze the effectiveness and safety of single‐agent rituximab (375 mg/m2 once weekly for 4 weeks) in naïve EMZL in a real‐life setting. The primary endpoint was the overall response rate (ORR), secondary endpoints were progression‐free (PFS), overall (OS) and disease‐free survivals (DFS), and drug tolerability. Fifty‐nine patients were analyzed. Median time between diagnosis and rituximab was 3.6 months. The ORR was 89.9%, with 67.8% complete response (CR). Median DFS and PFS were reached at 6.3 and 5.3 years, respectively. After a median follow‐up of 5 years, median OS was not reached. The most common adverse event was infusion reaction, reported in 28 cases, mainly during the first infusion and easily manageable. Single‐agent rituximab may represent a valid therapeutic option in the first‐line treatment of EMZL, at least for localized disease, with a favorable toxicity profile.
Extracellular vesicle and CRISPR gene therapy: Current applications in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease
Authors: Akyuz Enes , Aslan Feyza Sule , Gokce Enise , Ilmaz Oguzkan , Topcu Feyzullah , Kakac Seda 
Published: September 2024

AbstractNeurodegenerative diseases are characterized by progressive deterioration of the nervous system. Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) are prominently life‐threatening examples of neurodegenerative diseases. The complexity of the pathophysiology in neurodegenerative diseases causes difficulties in diagnosing. Although the drugs temporarily help to correct specific symptoms including memory loss and degeneration, a complete treatment has not been found yet. New therapeutic approaches have been developed to understand and treat the underlying pathogenesis of neurodegenerative diseases. With this purpose, clustered‐regularly interspaced short palindromic repeats/CRISPR‐associated protein (CRISPR/Cas) technology has recently suggested a new treatment option. Editing of the genome is carried out by insertion and deletion processes on DNA. Safe delivery of the CRISPR/Cas system to the targeted cells without affecting surrounding cells is frequently investigated. Extracellular vesicles (EVs), that is exosomes, have recently been used in CRISPR/Cas studies. In this review, CRISPR/Cas and EV approaches used for diagnosis and/or treatment in AD, PD, ALS, and HD are reviewed. CRISPR/Cas and EV technologies, which stand out as new therapeutic approaches, may offer a definitive treatment option in neurodegenerative diseases.
Effects of the manufacturing process on the flexural properties of EBMed lattice structures
Authors: Bellini Costanzo , Borrelli Rosario , Di Cocco Vittorio , Franchitti Stefania , Iacoviello Francesco , Mocanu Larisa Patricia , Sorrentino Luca 
Published: September 2024

AbstractLattice structures are very interesting since they present good mechanical properties coupled with lightness. Today, the maturity reached by additive manufacturing technologies allows the production of such structures. However, the mechanical properties of the constituting material can be affected by the process itself, because of the particular geometry. In fact, in a previous work, the mechanical characteristics of the bulk‐printed material were used for modelling the bending behavior of lattice‐cored specimens made of Ti6Al4V and produced through electron beam melting (EBM) process, but a certain discrepancy with experimental results was found. Therefore, in this work, a procedure was proposed to determine the mechanical properties of the material the lattice specimen is made of, in order to reduce the gap between the numerical and the experimental results. By considering the redetermined yield strength, such mismatch was reduced. Moreover, the metallographic analysis of the material found that the α laths of the α + β microstructure, typical of the studied alloy, were thinner than those of bulk specimens, and the presence of α′ martensite was discovered too. The fracture surface analysis determined a ductile failure mode for the lattice core while a fragile mode for the skins.
BYSTANDERS, JEWS, AND HISTORICAL INTERPRETATION
Authors: Dean Carolyn J. 
Published: September 2024

ABSTRACTThis article revisits the vast historiography on everyday life in Vichy France to address the moral questions and historical claims implicit in the bystander category. It addresses how historians conceive the relationship between bystanders and Jews, arguing that they implicitly erase the structural violence between the two groups by reproducing the liberal ethics implicit in the slogan “never again” in their own method—and in spite of their commitment to a boundary between history and memory. Drawing on the insights of postcolonial and political theory, it suggests that the category, if rethought, might account for popular complicity in genocidal violence.
PRIDASE 2024 guidelines for reporting diagnostic accuracy studies in endodontics: Explanation and elaboration
Authors: Pigg Maria , Nagendrababu Venkateshbabu , Duncan Henry F. , Abbott Paul V. , Fouad Ashraf F. , Kruse Casper , Patel Shanon , Rechenberg Dan K. , Suresh Nandini , Shetty Yedthare Naresh , Dummer Paul M. H. 
Published: September 2024

AbstractThe Preferred Reporting Items for Diagnostic Accuracy Studies in Endodontics (PRIDASE) 2024 guidelines are based on the Standards for Reporting of Diagnostic Accuracy Studies (STARD) 2015 guidelines and the Clinical and Laboratory Images in Publications (CLIP) principles, with the addition of items specifically related to endodontics. The use of the PRIDASE 2024 guidelines by authors and their application by journals during the peer review process will reduce the possibility of bias and enhance the quality of future diagnostic accuracy studies. The PRIDASE 2024 guidelines consist of a checklist containing 11 domains and 66 individual items. The purpose of the current document is to provide an explanation for each item on the PRIDASE 2024 checklist, along with examples from the literature to help readers understand their importance and offer advice to those developing manuscripts. A link to the PRIDASE 2024 explanation and elaboration document is available on the Preferred Reporting Items for study Designs in Endodontology (PRIDE) website (https://pride‐endodonticguidelines.org/pridase/) and on the International Endodontic Journal website (https://onlinelibrary.wiley.com/page/journal/13652591/homepage/pride‐guidelines.htm).
Multiomic‐based immune response profiling in migraine, vestibular migraine and Meniere's disease
Authors: Cruz‐Granados Pablo , Frejo Lidia , Perez‐Carpena Patricia , Amor‐Dorado Juan Carlos , Dominguez‐Duran Emilio , Fernandez‐Nava Maria Jose , Batuecas‐Caletrio Angel , Haro‐Hernandez Elisheba , Martinez‐Martinez Marta , Lopez‐Escamez Jose A. 
Published: September 2024

AbstractMigraine (MI) is the most common neurological disease, affecting with 20% of the world population. A subset of 25% of MI patients showcase concurrent vestibular symptoms, which may classify as vestibular migraine (VM). Meniere's disease (MD) is a complex inner ear disorder defined by episodes of vertigo associated with tinnitus and sensorineural hearing loss with a significant autoimmune/autoinflammatory contribution, which symptoms overlap with VM. Blood samples from 18 patients with MI (5), VM (5) and MD (8) and 6 controls were collected and compared in a case–control study. Droplet‐isolated nuclei from mononuclear cells used to generate scRNAseq and scATACseq data sets from MI, VM and MD. MI and VM have no differences in their immune transcriptome; therefore, they were considered as a single cluster for further analyses. Natural Killer (NK) cells transcriptomic data support a polarisation triggered by Type 1 innate immune cells via the release of interleukin (IL)‐12, IL‐15 and IL‐18. According to the monocyte scRNAseq data, there were two MD clusters, one inactive and one driven by monocytes. The unique pathways of the MI + VM cluster were cellular responses to metal ions, whereas MD monocyte‐driven cluster pathways showed responses to biotic stimuli. MI and MD have different immune responses. These findings support that MI and VM have a Type 1 immune lymphoid cell response, and that there are two clusters of MD patients, one inactive and one Monocyte‐driven.
Thirty‐day mortality risk in patients following radiofrequency and cryoballoon ablation for atrial fibrillation across the entire nation of Poland: An 8‐year analysis from the National Health Fund of Poland
Authors: Orczykowski Michal , Kowalski Marcin , Parikh Valay K. , Topczewska Magdalena , Urbanek Piotr , Robert Bodalski , Derejko Pawel , Glowniak Andrzej , Swierzynska‐Wodarska Ewa , Bilinska Maria , Szumowski Lukasz 
Published: September 2024

AbstractIntroductionAtrial fibrillation (AF) is the most common sustained arrhythmia, and catheter ablation (CA) is a primary therapeutic option. However, the 30‐day all‐cause mortality risk associated with CA for AF may be underestimated due to selection bias. Our study aimed to assess 30‐day mortality in an unselected cohort of patients.MethodsData from the National Health Fund‐Poland covered over 99% of nationwide radiofrequency ablation (RF) or cryoballoon ablation for AF, with 100% recorded deaths. The study included consecutive CA procedures in adult patients between 2012 and 2019. Thirty‐day mortality rates were calculated for each age group.ResultsA total of 31 214 CAs for AF were performed on 26 767 patients (34.8% female). Forty‐four percent of patients had hypertension, 31.2% had coronary artery disease, 14.4% had heart failure, 11% had diabetes mellitus, 5.6% had malignant neoplasms, 2.7% had a previous myocardial infarction, 2.5% had a previous stroke, and 2.2% had kidney disease. Thirty‐two deaths (0.1%) occurred within 30 days, with the highest mortality in the oldest age group (>80 years). Statistical analysis revealed higher incidences of kidney disease (p < 0.001) and heart failure (p = 0.001) in patients who died within 30 days. Mortality risk did not significantly differ between cryoballoon and RF ablation, as well as first and subsequent ablation for AF. The risk of death within 7 days postablation for AF was 1 in 2750 procedures, while the risk of death on the same day postablation was 1 in 6250 procedures.ConclusionsThe 30‐day mortality rate in a large, unselected AF ablation cohort, covering 99% of procedures in the country, is low except for the oldest patients. This factor should be taken into consideration when offering CA for AF.
Identification of novel M2 macrophage‐related molecule ATP6V1E1 and its biological role in hepatocellular carcinoma based on machine learning algorithms
Authors: Zhao Sen , Liu Meimei , Zhou Hua 
Published: September 2024

AbstractHepatocellular carcinoma (HCC) remains the most prevalent form of primary liver cancer, characterized by late detection and suboptimal response to current therapies. The tumour microenvironment, especially the role of M2 macrophages, is pivotal in the progression and prognosis of HCC. We applied the machine learning algorithm—CIBERSORT, to quantify cellular compositions within the HCC TME, focusing on M2 macrophages. Gene expression profiles were analysed to identify key molecules, with ATP6V1E1 as a primary focus. We employed Gene Set Enrichment Analysis (GSEA) and Kaplan–Meier survival analysis to investigate the molecular pathways and prognostic significance of ATP6V1E1. A prognostic model was developed using multivariate Cox regression analysis based on ATP6V1E1‐related molecules, and functional impacts were assessed through cell proliferation assays. M2 macrophages were the dominant cell type in the HCC TME, significantly correlating with adverse survival outcomes. ATP6V1E1 was robustly associated with advanced disease stages and poor prognostic features such as vascular invasion and elevated alpha‐fetoprotein levels. GSEA linked high ATP6V1E1 expression to critical oncogenic pathways, including immunosuppression and angiogenesis, and reduced activity in metabolic processes like bile acid and fatty acid metabolism. The prognostic model stratified HCC patients into distinct risk categories, showing high predictive accuracy (1‐year AUC = 0.775, 3‐year AUC = 0.709 and 5‐year AUC = 0.791). In vitro assays demonstrated that ATP6V1E1 knockdown markedly inhibited the proliferation of HCC cells. The study underscores the significance of M2 macrophages and ATP6V1E1 in HCC, highlighting their potential as therapeutic and prognostic targets.
Bullous pemphigoid burden of disease, management and unmet therapeutic needs
Authors: Werth V. P. , Murrell D. F. , Joly P. , Ardeleanu M. , Hultsch V. 
Published: September 2024

AbstractBullous pemphigoid (BP) is an autoimmune blistering disease that can have a profound negative impact on quality of life. BP most often affects the elderly, a population with a high medical burden and special safety concerns. In this review, we outline the BP disease course, diagnosis, epidemiology and comorbidities, and describe tools commonly used to assess BP disease activity and severity and the impact of BP on health‐related quality of life. We also outline biologic treatments currently under investigation for the treatment of BP and highlight the importance of considering safety when treating elderly patients.
Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real‐world data from a multicentre study
Authors: Nikolaou Vasiliki , Panou Evdoxia , Tsimpidakis Antonios , Koumprentziotis Ioannis‐Alexios , Patsatsi Aikaterini , Siakantaris Marina , Kruger‐Krasagakis Sabine‐Elke , Marinos Leonidas , Georgiou Elisavet , Lampadaki Kyriaki , Velissari Aliki , Daponte Athina‐Ioanna , Doxastaki Aikaterini , Kaliampou Stella , Vaiopoulos Aristeidis , Konstandinou Iliana , Koumourtzis Marios , Lakiotaki Eleftheria , Pappa Vassiliki , Tsamaldoupis Athanasios , Stratigos Alexander , Papadavid Evangelia 
Published: September 2024

AbstractBackgroundMethotrexate (MTX) has been a longstanding therapeutic option for mycosis fungoides (MF); however, data on its real‐world effectiveness remain limited.ObjectivesTo evaluate treatment‐related outcomes of oral MTX in patients with early‐ and late‐stage MF.MethodsThis is a retrospective multicentre analysis involving MF subjects from five referral centres for cutaneous lymphomas in Greece. Data regarding the effectiveness and safety were analysed.ResultsIn total, 211 MF patients were enrolled (males, 68.3%) with a median (IQR) age of diagnosis at 68.3 (56–75) years. Late‐stage (IIB‐IVB) disease was present in 124 patients (59.3%). MTX monotherapy was administered to 112 (53.1%) patients, with 99 receiving combination regimens with phototherapy, interferon and retinoids. MTX was used as first‐line regimen in 103 (48.9%) cases. An overall response rate (ORR) of 55.5% was observed with 29.9% of patients achieving complete responses. MTX demonstrated greater effectiveness as a first‐line treatment compared to subsequent use with no significant differences between monotherapy and combination therapy. The median time to best response was 3.8 months (IQR 2.3–9.9 months). Patients with erythrodermic disease (Stage III) had better ORRs compared to patients with tumour stage disease (Stage II) (61.1% vs. 44.8% respectively). The progression‐free survival (PFS) varied according to stage, with a median PFS of 17.1 months for early‐stage disease, 5.7 months for Stage IIB disease, 46 months for Stage III and 9.6 months for Stage IV disease (0.7‐.). Serious adverse (Grade 3) events leading to treatment discontinuation occurred in 14 (6.7%) cases. All patients received oral MTX once weekly with a median weekly dose of 15 mg/week (7.5–25).ConclusionOur findings support MTX as a viable treatment option for MF, particularly when used in the first‐line setting, offering a favourable benefit/risk profile. Response rates are stage‐dependent, with erythrodermic patients achieving superior and durable responses.